GATA3 and mature T-cell and NK-cell non-Hodgkin lymphoma: A significant difference in survival between GATA-3 PTCL patients receiving the current standard of care in the frontline setting (i.e., an anthracycline-based regimen) and those receiving palliative therapies (most commonly hospice care, summarized in Supplemental Table 1) was not observed, highlighting the need for improved therapeutic strategies in patients with GATA-3 PTCL.